Song Ting, Li Li, Wu Shaobo, Liu Yan, Guo Caiping, Wang Wen, Dai Lili, Zhang Tong, Wu Hao, Su Bin
Department of Infectious Diseases and Medical Immunology, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Beijing Key Laboratory for HIV/AIDS Research, Beijing, China.
Front Oncol. 2021 Mar 11;11:583714. doi: 10.3389/fonc.2021.583714. eCollection 2021.
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and has high mortality. Biomarkers related to HCC, such as alpha-fetoprotein, and imaging technology, such as ultrasound and computed tomography, have been used to screen and monitor HCC, but HCC is still difficult to diagnose effectively in the early stage due to the low sensitivity of the above mentioned traditional methods. There is an urgent need for noninvasive biomarkers to facilitate the screening and early diagnosis of HCC. With the advancement of next-generation sequencing, genetic biomarkers are becoming the core of cancer diagnosis. Genetic biomarkers such as peripheral blood circulating tumor DNA, microRNAs, long noncoding RNAs, circular RNAs, and exosomes have become the focus of early HCC diagnostics. HCC genetic biomarkers have been implemented in clinical practice. In this review, we describe the available literature on peripheral blood genetic biomarkers in the diagnosis of early HCC.
肝细胞癌(HCC)是全球最常见的癌症之一,死亡率很高。与HCC相关的生物标志物,如甲胎蛋白,以及成像技术,如超声和计算机断层扫描,已被用于筛查和监测HCC,但由于上述传统方法的低敏感性,HCC在早期仍难以有效诊断。迫切需要非侵入性生物标志物来促进HCC的筛查和早期诊断。随着下一代测序技术的进步,基因生物标志物正成为癌症诊断的核心。外周血循环肿瘤DNA、微小RNA、长链非编码RNA、环状RNA和外泌体等基因生物标志物已成为早期HCC诊断的焦点。HCC基因生物标志物已在临床实践中得到应用。在本综述中,我们描述了有关外周血基因生物标志物在早期HCC诊断中的现有文献。